PHOTOCURE ASA (PHO.OL) Stock Price & Overview
OSL:PHO • NO0010000045
Current stock price
The current stock price of PHO.OL is 65.7 NOK. Today PHO.OL is down by -12.05%. In the past month the price increased by 2.34%. In the past year, price increased by 16.28%.
PHO.OL Key Statistics
- Market Cap
- 1.782B
- P/E
- N/A
- Fwd P/E
- 126.31
- EPS (TTM)
- -0.06
- Dividend Yield
- N/A
PHO.OL Stock Performance
PHO.OL Stock Chart
PHO.OL Technical Analysis
ChartMill assigns a technical rating of 5 / 10 to PHO.OL. When comparing the yearly performance of all stocks, PHO.OL is a bad performer in the overall market: 60.03% of all stocks are doing better.
PHO.OL Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to PHO.OL. PHO.OL has a great financial health rating, but its profitability evaluates not so good.
PHO.OL Earnings
PHO.OL Forecast & Estimates
7 analysts have analysed PHO.OL and the average price target is 82.11 NOK. This implies a price increase of 24.98% is expected in the next year compared to the current price of 65.7.
For the next year, analysts expect an EPS growth of -64.6% and a revenue growth 14.74% for PHO.OL
PHO.OL Groups
Sector & Classification
PHO.OL Financial Highlights
Over the last trailing twelve months PHO.OL reported a non-GAAP Earnings per Share(EPS) of -0.06. The EPS increased by 54.03% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -0.21% | ||
| ROE | -0.31% | ||
| Debt/Equity | 0.21 |
PHO.OL Ownership
PHO.OL Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| SNW | SANOFI | 9.47 | 99.52B | ||
| SAN | SANOFI | 9.46 | 99.435B | ||
| 1SAN | SANOFI | 9.57 | 99.241B | ||
| 1MRK | MERCK KGAA | 15 | 51.435B | ||
| UNC | UCB SA | 24.1 | 51.331B | ||
| MRK | MERCK KGAA | 14.9 | 51.108B | ||
| UCB | UCB SA | 23.4 | 50.378B | ||
| BAYN | BAYER AG-REG | 9.09 | 40.633B | ||
| 1BAYN | BAYER AG-REG | 9.29 | 40.515B | ||
| IPN | IPSEN | 12.59 | 13.619B | ||
| REC | RECORDATI INDUSTRIA CHIMICA | 16.63 | 10.488B | ||
| TUB | FINANCIERE DE TUBIZE | N/A | 9.89B | ||
| VIRP | VIRBAC SA | 17.96 | 3.18B |
Related stock screener links
View all stocks in the Pharmaceuticals Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Oslo Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About PHO.OL
Company Profile
Photocure ASA engages in the development and commercialization of pharmaceutical products based on photodynamic technology. The company is headquartered in Oslo, Oslo and currently employs 102 full-time employees. The company went IPO on 2000-05-29. The firm is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Company’s activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.
Company Info
IPO: 2000-05-29
PHOTOCURE ASA
Hoffsveien 4
Oslo OSLO NO
Employees: 102
Phone: 4722062210
PHOTOCURE ASA / PHO.OL FAQ
What does PHO do?
Photocure ASA engages in the development and commercialization of pharmaceutical products based on photodynamic technology. The company is headquartered in Oslo, Oslo and currently employs 102 full-time employees. The company went IPO on 2000-05-29. The firm is focused on developing and improving photodynamic technology and owns a Photocure Technology platform, which develops photodynamic technology for diagnosis and therapy. Based on the Photocure Technology platform, Photocure has developed and commercialized Hexvix (Hyperthermic IntraVEsical Chemotherapy) and Cysview (hexaminolevulinate HCL) for use in bladder cancer. The Company’s activities are divided into two business segments: The Commercial Franchise and The Development Portfolio. The Commercial Franchise segment includes Hexvix/Cysview by geography (U.S. and Europe) and other sales (partners and other products including sales revenues for Hivec). The Development Portfolio segment includes development of pipeline products.
What is the stock price of PHOTOCURE ASA today?
The current stock price of PHO.OL is 65.7 NOK. The price decreased by -12.05% in the last trading session.
Does PHO stock pay dividends?
PHO.OL does not pay a dividend.
What is the ChartMill rating of PHOTOCURE ASA stock?
PHO.OL has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
Can you provide the sector and industry classification for PHOTOCURE ASA?
PHOTOCURE ASA (PHO.OL) operates in the Health Care sector and the Pharmaceuticals industry.
What is the market capitalization of PHO stock?
PHOTOCURE ASA (PHO.OL) has a market capitalization of 1.78B NOK. This makes PHO.OL a Small Cap stock.